her

Patritumab (U3-1287) is an anti-HER3 monoclonal antibody with potential antitumor activity and inhibits phosphorylation of EGFR, HER2, HER3, ERK, and AKT.Patritumab promotes apoptosis and inhibits proliferation in non-small cell lung cancer.

Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the treatment of B-cell chronic lymphocytic leukemia and rheumatoid arthritis.

Anti-HER3 ERBB3 Antibody (2Y512) is a mouse (varialbe region) human (kappa IgG1 constant) chimeric monoclonal antibody targeting Human HER3 ERBB3.

Anti-Dysadherin Antibody is a human-derived antibody expressed in CHO cells, targeting dysadherin. For isotype control, please refer to Human IgG1 kappa, Isotype Control.

The Anti-CD44 Antibody (Hermes-1) is a chimeric rat-derived IgG2a, κ antibody targeting human CD44. The isotype control for the Anti-CD44 Antibody (Hermes-1) is RatIgG2akappa, Isotype Control.

Anti-HER3 ERBB3 Antibody (4V862) is a Rabbit IgG monoclonal antibody targeting Human HER3 ERBB3.

Anti-HER3 ERBB3 Antibody (2W239) is a mouse (varialbe region) human (kappa IgG1 constant) chimeric monoclonal antibody targeting Human HER3 ERBB3.

Anti-HER3 ERBB3 Antibody (1P393) is a Mouse IgG1 monoclonal antibody targeting Human HER3 ERBB3.

Anti-CDH6 K-Cadherin Antibody (HKT288 antibody) is a human-derived antibody expressed in CHO cells that specifically targets CDH6. For isotype control, please refer to Human IgG1kappa, Isotype Control.

Anti-CDH17 Cadherin-17 Antibody (10C12) is a human-derived antibody produced in CHO cells, targeting CDH17. For isotype control, refer to HumanIgG1kappa, Isotype Control.

ABP-102 (CT P72) is a tetravalent IgG1-[L]-scFv bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for the selective targeting of HER2 overexpressing tumors. ABP-102 showed cytotoxicity in HER2-overexpressing models of breast and gastric cancers, while significantly decreasing activity against HER2 low level cells, twice as effective as rununmotamab.

Margetuximab (MGAH-22) is a second generation anti-human epidermal growth factor receptor 2 protein (HER2) monoclonal antibody with anti-tumor activity for the study of metastatic HER2-positive breast cancer and for the synthesis of nanomedicines.

Seribantumab (MM 121) is a humanized monoclonal antibody targeting HER3, inhibiting NRG1-induced growth in MCF-7 cells and patient-derived breast and lung cancer cells harboring NRG1 fusions or amplifications. It also induces apoptosis in MDA-MB-175-VII and LUAD-0061AS3 cells.

Gancotamab (MM-302) is a HER2-targeting polyethylene glycolated liposome that encapsulates adriamycin to facilitate delivery to HER2-overexpressing tumor cells while limiting exposure to non-target tissues, including the heart.Gancotamab has antitumor activity and may be used to study advanced HER2-positive breast cancer.

Zenocutuzumab (MCLA-128) is a humanized antibody targeting the extracellular domains of HER2 and HER3. It can be used for research on tumors driven by NRG1 gene rearrangement.

Inetetamab is a humanized monoclonal antibody targeting HER2 receptor domain IV, exhibiting antitumor activity through inducing pyroptosis in lung adenocarcinoma. It is used in studies of HER2-positive metastatic breast cancer.

Pembrolizumab (MK-3475) is a humanized monoclonal antibody inhibiting the PD-1 receptor and the first in the class of agents called the HER2 dimerization inhibitors that impairs the ability of HER2 to bind to other members of the HER family.

Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family.